























We claim:


1. An oral dosage form comprising a compound selected from:














	
	
	
	
	











	
	
	
	
	







































	
	
	
	
	













	
	
	
	
	








, or a pharmaceutically acceptable salt or prodrug thereof; and
a pharmaceutically acceptable carrier.











2. The oral dosage form of claim 1, comprising about 1 mg to about 1500 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
3. The oral dosage form of claim 1, comprising about 1 mg to about 1200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
4. The oral dosage form of claim 1, comprising about 1 mg to about 1000 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
5. The oral dosage form of claim 1, comprising about 1 mg to about 800 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
6. The oral dosage form of claim 1, comprising about 1 mg to about 600 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
7. The oral dosage form of claim 1, comprising about 1 mg to about 400 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
8. The oral dosage form of claim 1, comprising about 1 mg to about 300 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
9. The oral dosage form of claim 1, comprising about 1 mg to about 200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.













10. The oral dosage form of claim 1, comprising about 1 mg to about 100 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
11. The oral dosage form of claim 1, comprising about 10 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
12. The oral dosage form of claim 1, comprising about 30 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
13. The oral dosage form of claim 1, comprising about 100 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
14. The oral dosage form of claim 1, comprising about 200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
15. The oral dosage form of claim 1, comprising about 300 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
16. The oral dosage form of claim 1, comprising about 400 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
17. The oral dosage form of claim 1, comprising about 600 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
18. The oral dosage form of claim 1, comprising about 800 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
19. The oral dosage form of claim 1, comprising about 1000 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
20. The oral dosage form of claim 1, comprising about 1200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.













21. The oral dosage form of any one of claims 1-20, wherein the oral dosage form is a capsule.
22. The oral dosage form of any one of claims 1-20, wherein the oral dosage form is a tablet.
23. The oral dosage form of claim 22, wherein the tablet is a coated tablet.
24. A method of treating or preventing a disease or condition characterized by aberrant complement system activity, comprising orally administering to a patient in need thereof a therapeutically effective amount of a compound selected from:

















	
	
	
	
	











	
	
	
	
	
	











 <chem>CC(C)(O)c1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>	 <chem>CC1(CO1)c2cc3cc(OCc4ccccc4C(=O)O)ccc3oc2Cc5ccccc5N</chem>
 <chem>c1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>	 <chem>CC(C)c1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>
 <chem>CCCc1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>	 <chem>CC(C)C(=O)Nc1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>
 <chem>c1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>	 <chem>Cc1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>
 <chem>Cc1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>	 <chem>COc1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>
 <chem>Nc1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>	 <chem>COc1cc2cc(OCc3ccccc3C(=O)O)ccc2oc1Cc4ccccc4N</chem>
























	
	
	
	
	
















	
	
	
	
	



, or a pharmaceutically acceptable salt or prodrug thereof.

25. The method of claim 24, wherein the disease or condition characterized by aberrant complement system activity is an immunological disorder.

26. The method of claim 24, wherein the disease or condition characterized by aberrant complement system activity is a disease of the central nervous system.

27. The method of claim 24, wherein the disease or condition characterized by aberrant complement system activity is a neurodegenerative disease or neurological disease.

28. The method of claim 24, wherein the disease or condition characterized by aberrant complement system activity is a renal disease.

29. The method of claim 24, wherein the disease or condition characterized by aberrant complement system activity is a cardiovascular disease.

30. The method of claim 24, wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), warm autoimmune hemolytic anemia, IgA nephropathy, C3 glomerulonephritis, and focal segmental glomerulosclerosis.

31. The method of claim 24, wherein the disease or condition characterized by aberrant complement system activity is a hematological disorder.
32. The method of claim 24, wherein the disease or condition characterized by aberrant complement system activity is an ocular disorder or an eye disorder.
33. The method of claim 24, wherein the disease or condition characterized by aberrant complement system activity is macular degeneration, age-related macular degeneration (AMD), macular edema, diabetic macular edema, choroidal neovascularization (CNV), uveitis, Behcet's uveitis, proliferative diabetic retinopathy, non-proliferative diabetic retinopathy, glaucoma, hypertensive retinopathy, a corneal neovascularization disease, post-corneal transplant rejection, a corneal dystrophic disease, an autoimmune dry eye disease, Stevens-Johnson syndrome, Sjogren's syndrome, an environmental dry eye disease, Fuchs' endothelial dystrophy, retinal vein occlusion, or post-operative inflammation.
34. The method of claim 24, wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, organ transplant rejection, myasthenia gravis, neuromyelitis optica, membranoproliferative glomerulonephritis, dense-deposit disease, cold agglutinin disease, and catastrophic antiphospholipid syndrome.
35. The method of claim 34, wherein the disease is PNH.
36. The method of claim 35, wherein the PNH is characterized by one or more of hemolytic anemia, thrombosis, and impaired bone marrow function.
37. The method of any one of claims 34-36, wherein the orally administering suppresses hemolysis of erythrocytes or blocks C3 fragment deposition on erythrocytes or both.
38. The method of claim 37, wherein the suppression is greater than or equal to about 50%.
39. The method of claim 37, wherein the suppression is greater than or equal to about 80%.

40. The method of claim 37, wherein the suppression is greater than or equal to about 90%.
41. The method of claim 37, wherein the suppression is greater than or equal to about 95%.
42. The method of any one of claims 24-41, wherein the therapeutically effective amount is about 1 mg to about 1500 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
43. The method of claim 42, wherein the therapeutically effective amount is about 1 mg to about 1200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
44. The method of claim 42, wherein the therapeutically effective amount is about 1 to about 1000 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
45. The method of claim 42, wherein the therapeutically effective amount is about 1 to about 800 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
46. The method of claim 42, wherein the therapeutically effective amount is about 1 to about 600 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
47. The method of claim 42, wherein the therapeutically effective amount is about 1 to about 400 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
48. The method of claim 42, wherein the therapeutically effective amount is about 1 to about 300 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
49. The method of claim 42, wherein the therapeutically effective amount is about 1 to about 200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
50. The method of claim 42, wherein the therapeutically effective amount is about 1 to about 100 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

51. The method of claim 42, wherein the therapeutically effective amount is about 10 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
52. The method of claim 42, wherein the therapeutically effective amount is about 30 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
53. The method of claim 42, wherein the therapeutically effective amount is about 100 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
54. The method of claim 42, wherein the therapeutically effective amount is about 200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
55. The method of claim 42, wherein the therapeutically effective amount is about 300 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
56. The method of claim 42, wherein the therapeutically effective amount is about 400 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
57. The method of claim 42, wherein the therapeutically effective amount is about 600 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
58. The method of claim 42, wherein the therapeutically effective amount is about 800 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
59. The method of claim 42, wherein the therapeutically effective amount is about 1000 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
60. The method of claim 42, wherein the therapeutically effective amount is about 1200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
61. The method of any one of claims 24-60, wherein the compound or a pharmaceutically acceptable salt or prodrug thereof is administered once daily.

62. The method of any one of claims 24-60, wherein the compound or a pharmaceutically acceptable salt or prodrug thereof is administered twice daily.
63. The method of any one of claims 24-60, wherein the compound or a pharmaceutically acceptable salt or prodrug thereof is administered three times daily.
64. The method of any one of claims 24-63, wherein the compound or a pharmaceutically acceptable salt or prodrug thereof is administered as an oral dosage form of any one of claims 1-23.